FDA Warns Online Sellers Over Unapproved Semaglutide Injections Marketed Under Indian Drugmakers’ Brands

As Capitol Hill debates what the future of the U.S. generic drugs industry will look like, another alarm bell has rung at the Food and Drug Administration (FDA). This time, imported semaglutide generics – similar to Ozempic – sold by a company called the Cheap Medicine Shop were issued an FDA Warning Letter for marketing a drug that had not been approved for sale in the U.S.

Although Warning Letters do not always lead to product seizures or import bans (they should), the Sept. 24 letter to Cheap Medicine Shop reveals two things. First, American consumers are looking for the cheapest source of GLP-1 injectables, mostly sold as a weight loss tool. And second, exporters are using that demand to sell cheap goods, regardless of efficacy or safety profile. The good news is that at least this time the FDA flagged one — all the way from India, the leading source of generic drugs sold in the United States.

The letter said that the semaglutide generic, marketed as “Semanext Injection,” has not been approved, nor has the FDA received any drug applications for “Semanext Injection” offered to Americans at www.cheapmedicineshop.com. Current semaglutide products that are FDA-approved are only available by prescription.

The FDA flagged the sale from the Indian online retailer because the product – Semanext Injection – had not been registered and therefore not permitted for sale in the U.S. As a side note, the company behind the Semanext brand is Zydus Pharmaceuticals, and is licensed for sale worldwide by another Indian generics giant, Lupin Pharmaceuticals, according to a March 2026 press release about the brand and the partnership. The FDA did not mention these companies in their Warning Letter.

According to the FDA, Cheap Medicine Shop was selling unapproved and misbranded injectable semaglutide drugs to the American retail consumer online, without doctor approval.

Misbranded drugs, in this case, often means that it did not include sufficient side effect warnings. Moreover, unapproved generics – even if sold by a lab known to the FDA – do not carry the same assurances of safety and effectiveness as drugs subject to FDA oversight. Drugs that have circumvented FDA approval for sale could be contaminated, counterfeit, contain weak amounts of the necessary active ingredients, or contain different ingredients altogether that are not as effective. The FDA notes that,injectable drug products can also pose additional risks because they bypass many of the body’s natural defenses against toxic ingredients or dangerous organisms that can lead to serious or life-threatening conditions such as septicemia or sepsis – which results in blood poisoning or organ failure in a worst-case scenario.

“Semanext” and India’s GLP-1 Endeavors

Zydus Pharmaceuticals is the lab behind the generic semaglutide Semanext, and Lupin Pharmaceuticals is their licensing partner. The FDA has not accused Lupin or Zydus of illegally exporting pharmaceuticals, manufacturing defective drugs, or knowingly supplying an unauthorized U.S. seller. But the Semanext branding announcement in March should give the FDA an identifiable commercial supply chain to investigate rather than simply an obscure internet retailer. Cheap Medicine Shop does not appear to have anything to do with the two generic drug makers.

As of October 13, 2026, neither Zydus nor Lupin have an FDA-approved generic semaglutide product authorized for sale in the United States. Lupin received FDA approval in July 2025 for generic liraglutide, the active ingredient in the branded drug Victoza by Novo Nordisk. That’s a GLP-1 medication, but it is not semaglutide.

The FDA’s approved semaglutide products remain associated with Novo Nordisk, including Ozempic, Wegovy and Rybelsus. Lupin does have a semaglutide injectable, but it is not approved for sale in the U.S.

The India pharma giants are coming for the U.S. weight loss market.

Novo Nordisk’s 2025 SEC Form 20-F confirms that they reached a settlement with Zydus last year over U.S. patent litigation involving Ozempic. The terms are confidential. It’s possible that Zydus will be a first move on generic Ozempic in the U.S.

Cheap Medicine Shop isn’t a total anomaly.

On September 23, 2026, the FDA sent a Warning Letter to Online Generic Medicine, for marketing another unapproved injectable semaglutide product called Semanat Injection. That product has a separate Indian lab connection – Natco Pharma. The Economic Times, an Indian business daily, says Semanat is a Natco brand.

The Internet Corporation for Assigned Names and Numbers (ICANN) shows that both Online Generic Medicine and Cheap Medicine Shop are nearly 10 years old and do not reveal the name of their owners. Cheap Medicine Shop also lists Turks and Caicos island as an address, likely as the domain registrar and not the retailer’s actual office.

The question these two Warning Letters ask is – as India’s domestic generic GLP-1 industry expands, are unauthorized online sellers creating a secondary distribution channel into the U.S. market to bypass FDA approval?

There is now evidence of multiple online offerings. There is not yet evidence establishing their U.S. sales volumes, the authenticity of specific units, or that Indian drug makers are participating in these sales, which is unlikely. For now, entrepreneurial foreigners can advertise pharmaceuticals directly to Americans, sometimes bypassing traditional pharmacy distribution safeguards and actual prescriptions.

Novo Nordisk’s key semaglutide patent for the branded drug Wegovy expired in India on March 20, 2026, opening the market to lower-priced Indian generics now sold globally. Reuters reported that more than 40 Indian companies were preparing over 50 generic versions. They will be here soon enough.

September 2026 pharmaceutical sales data shows Indian generic brands had captured nearly 59% of their domestic semaglutide market. That’s a remarkable shift within six months of patent expiration.

India now has an increasingly competitive, low-cost semaglutide market, while Americans remain in a market where equivalent Indian-branded generics have not obtained FDA approval. This creates an economic incentive for unauthorized online sellers to target U.S. customers looking for cheap weight loss drugs without a doctor’s approval.

For some, the generic entrants are welcome. Wegovy prices have been cut by as much as 48%, depending on dosage. Ozempic prices were cut by as much as 36%. Their main competitors are all Indian – led by Zydus, Natco, Sun Pharma and Dr. Reddy’s. All entered the Indian market with substantially cheaper semaglutide alternatives.

Novo had previously reduced Wegovy prices in November 2025, ahead of Indian competition But even after those cuts, Indian generics will be significantly cheaper than Wegovy. Novo Nordisk announced in February that it will reduce the U.S. list price of Wegovy to $675 per month starting January 1, 2027, approximately 50% below its original price.

The latest headlines on GLP-1 generics will reveal yet again that the U.S. is hamstrung to compete with Indian labs once a drug is off-patent. If the U.S. wants a generic drug base, Washington will need to act. Novo Nordisk makes GLP-1 products in North Carolina.

For now, the United States still has patent protections on the GPL-1s and FDA approval requirements that prevent the Indian brands from being sold here as approved generics. The result is an emerging regulatory and price-arbitrage opportunity that unauthorized online sellers may exploit until the flood gates open.

At the very least, American consumers should not become the testing ground for products that have never cleared FDA approval.

The Semanext Injectable from the Cheap Medicine Shop was offered directly to U.S. consumers without a prescription and has been removed from its website. FDA said the patient risk for those who bought it prior to its removal was “material.”

FDA India Pharma Alerts

FDA records show three drug recalls over a three-day period beginning Sept. 15 that were attached to Indian pharmaceutical companies. Two were Class II recalls, which means there is a risk of non-lethal, adverse reactions to the drug, or that the drug might not work as prescribed. All three drugs were recalled due to failed impurities or dissolution specifications, raising concerns about the drug’s efficacy.

Cipla — Antibiotic recalled nationwide

FDA posted a recall of fosfomycin tromethamine granules for oral solution, an antibiotic used to treat urinary tract infections, on October 6. The recall was initiated in mid-September.

Ajanta Pharma — Heart medication recall nationwide

FDA classified a nationwide recall of ranolazine extended-release tablets of 1,000 mg. Ranolazine treats chronic angina associated with coronary artery disease.

Amneal — Injectable vitamin K recalled

FDA updated the classification of an existing recall involving phytonadione injectable emulsion, a vitamin K1 medicine used to treat or prevent certain bleeding problems.